JP6471099B2 - １，２５−ジヒドロキシビタミンｄを検出するための方法及びキット並びに関連する抗体 - Google Patents
１，２５−ジヒドロキシビタミンｄを検出するための方法及びキット並びに関連する抗体 Download PDFInfo
- Publication number
- JP6471099B2 JP6471099B2 JP2015554173A JP2015554173A JP6471099B2 JP 6471099 B2 JP6471099 B2 JP 6471099B2 JP 2015554173 A JP2015554173 A JP 2015554173A JP 2015554173 A JP2015554173 A JP 2015554173A JP 6471099 B2 JP6471099 B2 JP 6471099B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- lbd
- vdr
- monoclonal antibody
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 42
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 title claims description 31
- 102000009310 vitamin D receptors Human genes 0.000 claims description 54
- 108050000156 vitamin D receptors Proteins 0.000 claims description 54
- 108020001756 ligand binding domains Proteins 0.000 claims description 52
- 229930003316 Vitamin D Natural products 0.000 claims description 38
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 38
- 235000019166 vitamin D Nutrition 0.000 claims description 38
- 239000011710 vitamin D Substances 0.000 claims description 38
- 229940046008 vitamin d Drugs 0.000 claims description 38
- 102000005962 receptors Human genes 0.000 claims description 37
- 108020003175 receptors Proteins 0.000 claims description 37
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 37
- 238000001514 detection method Methods 0.000 claims description 30
- 238000009739 binding Methods 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000013060 biological fluid Substances 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000003018 immunoassay Methods 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 239000012148 binding buffer Substances 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 2
- 238000003556 assay Methods 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 12
- 239000002207 metabolite Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000003127 radioimmunoassay Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- -1 hydroxy vitamin D Chemical class 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 5
- 102000003982 Parathyroid hormone Human genes 0.000 description 5
- 108090000445 Parathyroid hormone Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000006255 nuclear receptors Human genes 0.000 description 5
- 108020004017 nuclear receptors Proteins 0.000 description 5
- 239000000199 parathyroid hormone Substances 0.000 description 5
- 229960001319 parathyroid hormone Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 4
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229920002704 polyhistidine Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000007430 reference method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001876 chaperonelike Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- BPKAHTKRCLCHEA-FOPGHSPUSA-N 19-Nor-1-α,25-dihydroxyvitamin D2 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C=C[C@H](C)C(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-FOPGHSPUSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 241001671553 Calophyllum antillanum Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000013612 Parathyroid disease Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 102100038611 Vitamin D-binding protein Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940083272 drisdol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940062743 hectorol Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 208000022560 parathyroid gland disease Diseases 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940052212 zemplar Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13152851.5 | 2013-01-28 | ||
| EP13152851.5A EP2759550B1 (en) | 2013-01-28 | 2013-01-28 | Method and kit for detecting 1,25-dihydroxyvitamin D and related antibodies |
| PCT/EP2014/051482 WO2014114780A1 (en) | 2013-01-28 | 2014-01-27 | Method and kit for detecting 1,25-dihydroxyvitamin d and related antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505634A JP2016505634A (ja) | 2016-02-25 |
| JP2016505634A5 JP2016505634A5 (OSRAM) | 2018-04-12 |
| JP6471099B2 true JP6471099B2 (ja) | 2019-02-13 |
Family
ID=47598742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015554173A Active JP6471099B2 (ja) | 2013-01-28 | 2014-01-27 | １，２５−ジヒドロキシビタミンｄを検出するための方法及びキット並びに関連する抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10196449B2 (OSRAM) |
| EP (3) | EP2759550B1 (OSRAM) |
| JP (1) | JP6471099B2 (OSRAM) |
| KR (1) | KR102196924B1 (OSRAM) |
| CN (1) | CN104955841B (OSRAM) |
| AU (1) | AU2014209857B2 (OSRAM) |
| CA (1) | CA2899350C (OSRAM) |
| DK (2) | DK2759550T3 (OSRAM) |
| ES (2) | ES2696075T3 (OSRAM) |
| PL (2) | PL2759550T3 (OSRAM) |
| PT (2) | PT2759550T (OSRAM) |
| WO (1) | WO2014114780A1 (OSRAM) |
| ZA (1) | ZA201505263B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2759550T (pt) | 2013-01-28 | 2018-11-16 | Diasorin S P A | Método e kit para detetar 1,25-di-hidroxivitamina d e anticorpos relacionados |
| US10983136B2 (en) | 2013-01-28 | 2021-04-20 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker |
| US11261257B2 (en) | 2013-01-28 | 2022-03-01 | Diasorin S.P.A. | Methods for detecting 1,25-dihydroxyvitamin D and related antibodies |
| CN104502599B (zh) * | 2014-12-19 | 2016-08-24 | 同昕生物技术（北京）有限公司 | 25-羟基维生素d定量检测试纸条及其应用 |
| WO2016113719A1 (en) * | 2015-01-18 | 2016-07-21 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker |
| KR20180104080A (ko) | 2016-01-22 | 2018-09-19 | 아피메딕스, 인코포레이티드 | 비타민 d 대사산물 검출용 장치 |
| US10247728B1 (en) * | 2016-03-17 | 2019-04-02 | Charm Sciences, Inc. | Method and assay for detection of residues |
| EP3401681B1 (en) | 2017-05-11 | 2023-03-29 | Boditech Med Inc. | Method for quick quantification assay of vitamin d based on fluorescence measurement using lateral flow cartridge |
| CN108362688B (zh) * | 2018-01-02 | 2021-08-24 | 北京利德曼生化股份有限公司 | 一种25羟基维生素d磁微粒化学发光检测试剂盒 |
| EP3760640A4 (en) * | 2018-02-27 | 2021-11-17 | Shimadzu Corporation | ANTIBODIES SPECIFICALLY RECOGNIZING THE N-TERMINAL END OF APP669-X, AND METHOD OF IMMUNOLOGICAL ASSAY |
| WO2020023899A1 (en) * | 2018-07-27 | 2020-01-30 | Veravas, Inc. | Methods for depletion and enrichment |
| CN109601477A (zh) * | 2018-12-21 | 2019-04-12 | 云南农业大学 | 一种基于维生素d受体血液生化标记选育武定鸡的方法 |
| CN110058028B (zh) * | 2019-05-05 | 2021-03-02 | 苏州长光华医生物医学工程有限公司 | 一种24,25-双羟基维生素d免疫检测试剂盒及其应用 |
| CN113999311B (zh) * | 2020-07-28 | 2022-11-04 | 东莞市朋志生物科技有限公司 | 可特异性结合25-羟基维生素d的抗体、其应用以及诊断试剂盒 |
| CN113884687B (zh) * | 2021-12-08 | 2022-02-11 | 南京岚轩生物科技有限公司 | 用于检测25-羟基维生素d含量的解离剂及其制备方法 |
| CN119080938B (zh) * | 2023-06-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒 |
| CN119827779A (zh) * | 2023-10-12 | 2025-04-15 | 菲鹏生物股份有限公司 | 维生素d均相检测方法和试剂 |
| CN119846237B (zh) * | 2024-11-22 | 2025-10-31 | 厦门康基生物科技有限公司 | 一种基于VDR和RXRα双夹心检测25-OH-VD的方法 |
| CN119322137A (zh) * | 2024-12-17 | 2025-01-17 | 凯莱谱科技股份有限公司 | 血清维生素d代谢通路代谢物的液相色谱串联质谱检测方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8408193D0 (en) | 1984-03-30 | 1984-05-10 | Cambridge Patent Dev | Antibodies |
| US4816417A (en) * | 1987-08-14 | 1989-03-28 | Wisconsin Alumni Research Foundation | Assay for 1,25-dihydroxy vitamin D in sample containing vitamin D transport protein |
| US5260199A (en) * | 1991-07-30 | 1993-11-09 | Wisconsin Alumni Research Foundation | Method of producing 1,25-dihydroxyvitamin D3 receptor protein |
| JPH06109727A (ja) * | 1992-08-14 | 1994-04-22 | Wisconsin Alumni Res Found | １，２５−ジヒドロキシビタミンｄの検定法 |
| KR940009957A (ko) * | 1992-10-09 | 1994-05-24 | 정명식 | 높은 보자력을 갖는 코발트/파라디움 광자기 다층박막 및 그 제조방법 |
| JPH07330800A (ja) * | 1994-06-08 | 1995-12-19 | Yamasa Shoyu Co Ltd | ビタミンｄ受容体に対するモノクローナル抗体 |
| US6516294B1 (en) | 1999-07-01 | 2003-02-04 | The Regents Of The University Of California | Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor |
| DE602008001667D1 (de) * | 2007-02-01 | 2010-08-12 | Immundiagnostik Ag | Direktbestimmung von vitamin d im serum oder plasma |
| US8962239B2 (en) * | 2008-04-02 | 2015-02-24 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| GB0903469D0 (en) * | 2009-03-02 | 2009-04-08 | Axis Shield Diagnostics Ltd | Assay |
| EP2427484B1 (en) | 2009-05-06 | 2016-07-06 | OPKO Ireland Global Holdings, Limited | Method and composition for measuring the amount of vitamin d derivatives |
| EP2457916A1 (en) * | 2010-11-16 | 2012-05-30 | DiaSorin S.p.A. | Compound for the covalent attachment of the chemiluminescent probe N-(4-Aminobutyl)-N-ethylisoluminol (ABEI) to target molecules and uses thereof |
| GB201101801D0 (en) * | 2011-02-02 | 2011-03-16 | Axis Shield Diagnostics Ltd | Binding molecule and method for measuring |
| KR20140074307A (ko) | 2011-08-26 | 2014-06-17 | 아스튜트 메디컬 인코포레이티드 | 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물 |
| WO2013042426A1 (ja) | 2011-09-21 | 2013-03-28 | 富士レビオ株式会社 | 親和性複合体に対する抗体 |
| US10983136B2 (en) * | 2013-01-28 | 2021-04-20 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker |
| PT2759550T (pt) | 2013-01-28 | 2018-11-16 | Diasorin S P A | Método e kit para detetar 1,25-di-hidroxivitamina d e anticorpos relacionados |
-
2013
- 2013-01-28 PT PT13152851T patent/PT2759550T/pt unknown
- 2013-01-28 PL PL13152851T patent/PL2759550T3/pl unknown
- 2013-01-28 DK DK13152851.5T patent/DK2759550T3/en active
- 2013-01-28 EP EP13152851.5A patent/EP2759550B1/en active Active
- 2013-01-28 ES ES13152851T patent/ES2696075T3/es active Active
-
2014
- 2014-01-27 US US14/763,264 patent/US10196449B2/en active Active
- 2014-01-27 CA CA2899350A patent/CA2899350C/en active Active
- 2014-01-27 DK DK14702498.8T patent/DK2948474T3/da active
- 2014-01-27 JP JP2015554173A patent/JP6471099B2/ja active Active
- 2014-01-27 AU AU2014209857A patent/AU2014209857B2/en active Active
- 2014-01-27 WO PCT/EP2014/051482 patent/WO2014114780A1/en not_active Ceased
- 2014-01-27 KR KR1020157022534A patent/KR102196924B1/ko active Active
- 2014-01-27 PL PL14702498T patent/PL2948474T3/pl unknown
- 2014-01-27 PT PT147024988T patent/PT2948474T/pt unknown
- 2014-01-27 EP EP19212047.5A patent/EP3650467A1/en not_active Withdrawn
- 2014-01-27 ES ES14702498T patent/ES2780823T3/es active Active
- 2014-01-27 CN CN201480006190.6A patent/CN104955841B/zh active Active
- 2014-01-27 EP EP14702498.8A patent/EP2948474B1/en active Active
-
2015
- 2015-07-21 ZA ZA2015/05263A patent/ZA201505263B/en unknown
-
2017
- 2017-05-26 US US15/606,284 patent/US10501548B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL2948474T3 (pl) | 2020-07-27 |
| EP2948474A1 (en) | 2015-12-02 |
| PL2759550T3 (pl) | 2019-01-31 |
| WO2014114780A1 (en) | 2014-07-31 |
| US10501548B2 (en) | 2019-12-10 |
| PT2948474T (pt) | 2020-03-05 |
| EP2759550A1 (en) | 2014-07-30 |
| DK2948474T3 (da) | 2020-03-09 |
| ES2696075T3 (es) | 2019-01-14 |
| CN104955841A (zh) | 2015-09-30 |
| PT2759550T (pt) | 2018-11-16 |
| AU2014209857A1 (en) | 2015-08-13 |
| DK2759550T3 (en) | 2018-11-26 |
| ES2780823T3 (es) | 2020-08-27 |
| EP3650467A1 (en) | 2020-05-13 |
| EP2759550B1 (en) | 2018-08-15 |
| CN104955841B (zh) | 2018-05-04 |
| JP2016505634A (ja) | 2016-02-25 |
| KR102196924B1 (ko) | 2020-12-31 |
| KR20150110680A (ko) | 2015-10-02 |
| US20150361178A1 (en) | 2015-12-17 |
| AU2014209857B2 (en) | 2018-10-04 |
| HK1218129A1 (en) | 2017-02-03 |
| CA2899350C (en) | 2023-01-10 |
| US10196449B2 (en) | 2019-02-05 |
| ZA201505263B (en) | 2016-06-29 |
| US20170267770A1 (en) | 2017-09-21 |
| EP2948474B1 (en) | 2020-01-15 |
| CA2899350A1 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6471099B2 (ja) | １，２５−ジヒドロキシビタミンｄを検出するための方法及びキット並びに関連する抗体 | |
| US20240085438A1 (en) | Adrenomedullin assays and methods for determining mature andrendomedullin | |
| JP6602884B2 (ja) | ビタミンｄの測定法 | |
| US20240103021A1 (en) | Adrenomedullin assays and methods for determining mature andrendomedullin | |
| CA2716280A1 (en) | Biomarkers | |
| US10421812B2 (en) | Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof | |
| US11261257B2 (en) | Methods for detecting 1,25-dihydroxyvitamin D and related antibodies | |
| CN110352351B (zh) | 使用抗人bnp片段(4-32)抗体的免疫测定方法 | |
| WO2015046444A1 (ja) | 抗アルドステロン抗体 | |
| JP2014091719A (ja) | ヒトｂ型ナトリウム利尿ペプチドの３−３２位に相当するポリペプチドに対する特異抗体およびそれを用いた測定法 | |
| HK1218129B (en) | Method and kit for detecting 1,25-dihydroxyvitamin d and related antibodies | |
| JP2014028770A (ja) | ヒトｂ型ナトリウム利尿ペプチド特異抗体およびそれを用いた測定法 | |
| JP2011160696A (ja) | 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体 | |
| JP2015137272A (ja) | 新規のペプチド及び疾患の検出方法 | |
| BR112017008985B1 (pt) | Método in vitro para a determinação da concentração de 25-hidroxivitamina d, uso de um método in vitro, uso de um primeiro agente de ligação e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170120 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171205 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180822 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181017 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190108 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190121 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6471099 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |